

CASE REPORT

Open Access

Localized retroperitoneal Castleman's disease: a case report and review of the literature

Rodrigo Aguilar-Rodriguez¹, Sorin-Lucian Milea¹, Ilhan Demirci^{1*}, Susanne Herold², Michael Flasshove³, Bernd Klosterhalfen⁴, Horst Kinkel⁵ and Hermann Janßen¹

Abstract

Introduction: Castleman's disease, also known as angiofollicular lymph node hyperplasia, is a rare disease with two known expansion types, unicentric and multicentric, which play a major role in determining therapy. We focus here on the unicentric type, which can be treated and cured by surgery. To date, approximately 1000 cases of Castleman's disease have been reported in the literature.

Case presentation: A 50-year-old Caucasian woman presented to our Department of Hematology and Internal Oncology with increasing fatigue as her sole symptom. Diagnostic investigations including laboratory studies, ultrasound, computed tomography and magnetic resonance imaging were performed. These revealed an interaortocaval, retroperitoneal tumor mass in her upper abdomen as the only manifestation of the disease. No enlarged lymph nodes were detected. We conducted a laparotomy with radical extirpation of the tumor mass (10×9×5.7cm). Complete tumor resection with clear margins was achieved. A pathological analysis of the resected sample showed atypical lymphoid tissue of small to medium cells with some clearly visible nucleoli, enlarged sinusoidal vessels, pleomorphic calcifications and focally preserved germinal-center-like structures. Histological and immunohistochemical analysis confirmed the diagnosis of Castleman's disease: staining for CD3, CD5, CD10, CD20, CD23, CD79 and Ki-67 was strongly positive in the germinal-center-like structures. Histological findings clearly showed the disease to be the hyaline vascular subtype. Staining for cyclin D1 and CD30 was negative. Expression of CD15 was positive in the enlarged sinusoidal vessels. A supplementary clonality analysis was without pathological findings. Tests for human immunodeficiency virus and human herpes virus 8 were negative and results from a bone marrow biopsy were normal. Our patient recovered well from surgery and was discharged from our hospital. To date, no recurrence of the disease has been detected.

Conclusion: Castleman's disease is a rare disorder that remains a diagnostic challenge. Radical surgical resection is considered to be the gold standard for treating the unicentric variant of this disease.

Keywords: Castleman's disease, Hyaline vascular variant, Surgery, Unicentric

Introduction

Castleman's disease, also known as angiofollicular lymph node hyperplasia, is a rare disorder first described by Benjamin Castleman in the mid-1950s. There are two known expansion types of this disease, unicentric and multicentric, which play a major role in determining therapy. We focus here on the unicentric type, which can be treated and cured by surgery. Because of the rarity of this disease, epidemiological data like prevalence

or incidence are not available. The average age of patients with unicentric Castleman's disease is around 30 to 40 years old. Patients with the multicentric form are usually around 50 to 60 years old. No dispositional age, race or sex seems to exist but the disease is widely associated with human herpes virus 8 (HHV-8) and human immunodeficiency virus (HIV) infection [1-4]. To date, approximately 1000 cases of Castleman's disease have been reported in the literature [5].

Case presentation

In October 2011, a 50-year-old Caucasian woman presented to our Department of Hematology and Internal

* Correspondence: Ilhan.Demirci@Krankenhaus-Dueren.de

¹Department of General, Visceral, Vascular and Thoracic Surgery, Hospital of Düren, Düren, Germany

Full list of author information is available at the end of the article

Oncology with increasing fatigue as her sole symptom. Diagnostic investigations including laboratory studies, ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI) were performed. These revealed an interaortocaval, retroperitoneal tumor mass in her upper abdomen as the only manifestation of the disease (Figure 1). No enlarged lymph nodes were detected. We conducted a laparotomy with radical extirpation of a tumor mass of approximately 10×9×5.7cm and unknown dignity (Figure 2). Complete tumor resection with clear margins was achieved.

A pathological analysis showed atypical lymphoid tissue of small to medium cells with some clearly visible nucleoli, enlarged sinusoidal vessels, pleomorphic calcifications and focally preserved germinal-center-like structures. Histological and immunohistochemical analysis confirmed the diagnosis of Castleman's disease (see Figure 2): staining for CD3, CD5, CD10, CD20, CD23, CD79 and Ki-67 was strongly positive in the germinal-center-like structures. Histological findings clearly showed the disease to be the

hyaline vascular subtype. Staining for cyclin D1 and CD 30 was negative. Expression of CD15 was positive in the above-mentioned enlarged sinusoidal vessels. A supplementary clonality analysis was without pathological findings. Tests for HIV and HHV-8 were negative and results of a bone marrow biopsy were normal. Our patient recovered well from the surgery and was discharged from our hospital in early November. Follow-up care was carried out by our Department of Hematology and Internal Oncology. At the time of writing, no recurrence of the disease had been detected.

Discussion

The histological subtypes of Castleman's disease are as follows: hyaline vascular variant (unicentric in 72% of all cases); plasma cell variant (unicentric in 18% and multicentric in 10% of all cases); mixed variant, and a plasmablastic variant of multicentric Castleman's disease [3,4,6-10]. The disease may occur anywhere in the lymphatic system but is found in the thorax in 60% to




Figure 1 Pre-operative ultrasound, computed tomography and magnetic resonance imaging scans showing an interaortocaval tumor mass of approximately 6.3×4.7×6.8cm (measured on computed tomography scan).




Figure 2 Intra-operative pictures of the tumor *in situ* and after resection. Hematoxylin and eosin staining and exemplary immunohistochemical staining for CD20 and for CD3. (A, C) Intraoperative pictures of the tumor in situ. (B) Resected tumor mass. (D) Hematoxylin and eosin staining showing hyaline vascular subtype. (E) Immunohistochemical staining for CD20. (F) Immunohistochemical staining for CD3.

70% of cases. The mediastinum is the most common localization for the unicentric type; a retroperitoneal multicentric type is among the rarest. Only 10% to 17% of cases involve the abdomen, of which the majority of cases are retroperitoneal [3,11-14] (Table 1). The plasmablastic variant of the disease is commonly associated with HHV-8 and tends to have a poor prognosis. It occurs more frequently in patients who are HIV positive, although there seems to be no correlation with CD4 count [15]. The multicentric and, especially, HHV-8-positive types are risk factors for the development of Hodgkin lymphoma, non-Hodgkin lymphoma and Kaposi sarcoma. Non-Hodgkin lymphomas are mainly characterized as B-cell lymphoma subtypes (71%). Less frequently associated non-Hodgkin lymphomas are plasmacytoma and T-cell lymphoma [5,16,17]. In a 2009 study, Fazakas *et al.* supposed a possible etiological relationship between a coexistent

HHV-6 infection and multicentric plasmocytic Castleman's disease with POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes) [18].

The extent of clinical symptoms may vary widely. Unspecific symptoms like asymptomatic to symptomatic lymphadenopathy accompanied by fever, anemia, fatigue, abdominal or thoracic pain, and weight loss can be observed. Cutaneous symptoms like paraneoplastic pemphigus, erythema multiforme or lichen planus have been described. POEMS syndrome is also known to be associated with the disease, commonly with HHV-8-positive forms.

Laboratory studies with blood counts and measurement of C-reactive protein, interleukin 6 and liver function should be conducted. In addition, HIV and HHV-8 testing should be performed. In this context, it is interesting to

Table 1 Overview of the histological variants and sex and age distribution of localized retroperitoneal Castleman's disease in the literature

Histological variants				Distribution of sex			Distribution of age (in years)			
HV	PC	Mixed	NK	M	F	NK	Age	M	F	NK
148	9	5	37	69	79	51	0 to 9	2	0	52
74.37%	4.52%	2.51%	18.59%	34.67%	39.7%	25.63%	10 to 19	9	6	
							20 to 29	7	21	
							30 to 39	16	18	
							40 to 49	14	13	
							50 to 59	7	7	
							60 to 69	12	3	
							70 to 79	1	0	
In total: 199 cases				M:F ratio: 1:1.14			Mean	38.25		

F, female; HV, hyaline vascular; M, male; NK, not known; PC, plasma cell.

Table 2 Overview of therapy, outcome and follow-up periods of localized retroperitoneal Castleman's disease in the literature

Histological variants	Therapy						Outcome			Follow-up			
	CR	LR	PR	RT	CN	NK	UNEV	COMP	NK	NREC	REC	Deceased	NK
HV (n = 137)	77	4	4	1	0	51	67	2	67	37	0	3	97
PC (n = 9)	7	0	0	0	1	1	4	1	3	5	0	1	3
Mixed (n = 5)	5	0	0	0	0	0	3	0	2	3	0	0	2
NK (n = 37)	1	0	0	0	0	26	0	0	37	0	0	0	37

COMP, complicated postoperative course; CN, conservative; CR, conventional resection; HV, hyaline vascular; LR, laparoscopic resection; NK, not known; NREC, no recurrence; PC, plasma cell; PR, partial resection; REC, recurrence; RT, radiation therapy; UNEV, uneventful postoperative course.

note that false-positive D-dimer and negative fibrin(ogen) degradation product levels have been described in the literature [19]. Although pathological analysis still remains the gold standard for diagnosis, MRI, contrast-enhanced sonography, angiography and CT are valuable diagnostic tools [20]. MRI can be helpful in identifying the hypervascular appearance of the hyaline vascular type [21]. As Michail *et al.* stated, Castleman's disease should be included in the differential diagnosis of any hypervascular and heterogeneous tumor mass in the retroperitoneum [22,23]. In this regard, one should note a recently published case report of unicentric hyaline vascular Castleman's disease mimicking a paraspinal schwannoma [24].

Kim *et al.* described two distinctive types of radiological manifestation in abdominal Castleman's disease: a localized type with single or multiple discrete masses, and a disseminated type with non-specific organomegaly and lymphadenopathy [25]. Differences in enhancement between the plasma cell and hyaline vascular variants on CT scans have been described previously. The hyaline vascular variant is known for its high enhancement on CT imaging, whereas the plasma cell variant shows only low enhancement. However, Lu and Wu pointed out that the degree of enhancement cannot be used as a reliable and specific diagnostic criterion to distinguish between the above-mentioned types [13]. In a recently published study, 'rim-like' enhancement, a predominantly left-sided location in the retroperitoneum, and the presence of peritoneal thickening were described as relatively characteristic CT findings of the disease. Furthermore, non-specific features like necrosis, fibrosis and calcifications can be observed [14]. A fluorine-18-fluorodeoxyglucose positron emission tomography scan can be helpful in staging of the disease, but its role is still controversial.

Castleman's disease remains difficult to diagnose preoperatively because the disease may resemble other malignant tumors. Therefore, exclusion of other diseases with lymphadenopathy, for example lupus erythematoses, thymoma, sarcoma, rheumatoid arthritis, HIV infection and lymphoma, is important for differential

diagnosis [3]. According to Deschênes *et al.*, fine-needle aspiration can be useful in diagnosing Castleman's disease [26]. The unicentric type - if resected completely - is not associated with increased mortality and is known to have an excellent prognosis (Table 2). Therefore, radical surgical resection is considered to be the gold standard therapy in these cases. According to a recently published study, there are no differences in the surgical outcomes of deep and superficial Castleman's disease as long as the resection is complete [27]. The prognosis and outcome of the multicentric type depend on many factors, like progression rate, infections and comorbidities, and tend to be poorer [2,4,6]. There are no clear data about how long follow-up care should be conducted. Patients treated with radiotherapy should be closely monitored with CT scans every six months. Patients with unicentric disease should receive radiological follow-up every six to 12 months, although a generally accepted regimen is not established [2,4]. Appropriate follow-up care should consider type, progression rate, clinical course and curability of the disease, and should always therefore be planned on a case-by-case basis.

Conclusion

Castleman's disease is a rare disorder that remains a diagnostic challenge. Radical surgical resection is considered to be the gold standard for treating the unicentric variant. This type is not associated with increased mortality as long as resection is radical and complete.

Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations

CT: computed tomography; HHV-8: human herpes virus 8; HIV: human immunodeficiency virus; MRI: magnetic resonance imaging; POEMS: polyneuropathy organomegaly, endocrinopathy or edema, M-protein, skin changes.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

RAR prepared and drafted the manuscript and performed the literature research. SLM edited the manuscript and performed the literature research. ID edited the manuscript and performed the literature research. SH edited the manuscript. BK performed the immunohistochemical staining and examination of the specimen, and edited the manuscript. MF edited the manuscript. HK performed the ultrasound scan and edited the manuscript. HJ was the operating surgeon and was involved in the preparation, drafting and editing of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors thank Mr Erhan Demirci for his technical and advisory support.

Author details

¹Department of General, Visceral, Vascular and Thoracic Surgery, Hospital of Düren, Düren, Germany. ²Department of Internal Medicine II, University of Gießen Lung Center, Gießen, Germany. ³Department of Hematology and Internal Oncology, Hospital of Düren, Düren, Germany. ⁴The Institute of Pathology, Hospital of Düren, Düren, Germany. ⁵Department of Gastroenterology, Hepatology and Diabetology, Hospital of Düren, Düren, Germany.

Received: 2 October 2013 Accepted: 11 February 2014

Published: 10 March 2014

References

1. Al-Natour S, Sawalhi S, Al-Muhtady D, Hijazi E: Mesenteric Castleman's disease: case report and literature review. *Asian J Surg* 2010, **33**:150-153.
2. Casper C: The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. *Br J Haematol* 2005, **129**:3-17.
3. Park JB, Hwang JH, Kim H, Choe HS, Kim YK, Kim HB, Bang SM: Castleman disease presenting with jaundice: a case with the multicentric hyaline vascular variant. *Korean J Intern Med* 2007, **22**:113-117.
4. Vries IAC, van Acht MMS, Demeyere TB, Lybeert MLM, Zoete JP, Nieuwenhuijzen GAP: Neoadjuvant radiotherapy of primary irresectable unicentric Castleman's disease: a case report and review of the literature. *Radiat Oncol* 2010, **5**:7.
5. Talat N, Schulte KM: Castleman's disease: systematic analysis of 416 patients from the literature. *Oncologist* 2011, **16**:1316-1324.
6. Karami H, Sahebpoor AA, Ghasemi M, Karami H, Dabirian M, Vahidshahi K, Masiha F, Shahmohammadi S: Hyaline vascular-type Castleman's disease in the hilum of liver: a case report. *Cases J* 2010, **3**:74.
7. Xia D, Wang S, Li QM, Chen SW, Zhong J, Meng HZ, Jin BY, Cai SL: Laparoscopic approach of Castleman's disease in the pararenal retroperitoneum: report of two cases. *Chin Med J* 2010, **123**:1809-1811.
8. Castleman B, Iverson L, Menendez VP: Localized mediastinal lymphnode hyperplasia resembling thymoma. *Cancer* 1956, **9**:822-30.
9. Flendrig JA: Benign giant lymphoma: the clinical signs and symptoms and the morphological aspects. *Folia Medica* 1969, **12**:119-120.
10. Keller AR, Hochholzer L, Castleman B: Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. *Cancer* 1972, **29**:670-683.
11. Erkan N, Yildirim M, Selek E, Sayhan S: Peripancreatic Castleman disease. *JOP* 2004, **5**:491-494.
12. Han SL, Chen XX, Zheng XF, Yan JY, Shen X, Zhu GB: The clinicopathological behaviour and surgical treatment of abdominal Castleman's disease. *Singapore Med J* 2010, **51**:813-816.
13. Lu ZH, Wu M: Localized Castleman disease of plasma cell type in the abdomen. *Chin Med J* 2011, **124**:2789-2791.
14. Zheng X, Pan K, Cheng J, Dong L, Yang K, Wu E: Localized Castleman disease in retroperitoneum: newly discovered features by multi-detector helical CT. *Abdom Imaging* 2008, **33**:489-492.
15. Cronin DMP, Warnke RA: Castleman disease: an update on classification and the spectrum of associated lesions. *Adv Anat Pathol* 2009, **16**:236-246.
16. Weisenburger DD, Nathwani BN, Winberg CD, Rappaport H: Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. *Hum Pathol* 1985, **16**:162-172.
17. Larroche C, Cacoub P, Soulier J, Oksenhendler E, Clauvel JP, Piette JC, Raphael M: Castleman's disease and lymphoma: report of eight cases in HIV-negative patients and literature review. *Am J Hematol* 2002, **69**:119-126.
18. Fazakas A, Csire M, Berencsi G, Szepesi A, Matolcsy A, Jakab L, Karádi I, Várkonyi J: Multicentric plasmocytic Castleman's disease with polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes syndrome and coexistent human herpes virus-6 infection—a possible relationship. *Leuk Lymphoma* 2009, **50**:1661-1665.
19. Mugler K, Lefkowitz JB: False-positive D-dimer result in a patient with Castleman disease. *Arch Pathol Lab Med* 2004, **128**:328-331.
20. Annunziata G, Martino P, Palazzo S, Vasti MP, Ditunno P, Lucarelli G, Selvaggi FP: US with contrast medium in the diagnosis of abdominal Castleman's disease. *Arch Ital Urol Androl* 2005, **77**:76-78.
21. Ferrozzi F, Tognini G, Spaggiari E, Pavone P: Focal Castleman disease of the lung: MRI findings. *Clin Imaging* 2001, **25**:400-402.
22. Michail OP, Tsirkinidis P, Androulaki A, Georgiou C, Angelopoulou M, Griniatsos J: Retroperitoneal pararenal Castleman's disease. *West Indian Med J* 2009, **58**:61-64.
23. Zhang J, Song N, Liu B, Hua L, Wang Z, Yin C, Zhang W: A case report of unusual retroperitoneal Castleman's disease in an old woman. *Urol Int* 2012, **89**:369-372.
24. Nagano S, Yokouchi M, Yamamoto T, Kaieda H, Setoguchi T, Hiraki T, Tashiro Y, Yonezawa S, Komiya S: Castleman's disease in the retroperitoneal space mimicking a paraspinal schwannoma: a case report. *World J Surg Oncol* 2013, **11**:108.
25. Kim TJ, Han JK, Kim YH, Kim TK, Choi BI: Castleman disease of the abdomen: imaging spectrum and clinicopathologic correlations. *J Comput Assist Tomogr* 2001, **25**:207-214.
26. Deschênes M, Michel RP, Tabah R, Auger M: Fine-needle aspiration cytology of Castleman disease: case report with review of the literature. *Diagn Cytopathol* 2008, **36**:904-908.
27. Chen CH, Liu HC, Tung KY, Lee JJ, Liu CL, Liu TP: Surgical outcome of superficial and deep Castleman disease. *ANZ J Surg* 2007, **77**:339-343.

doi:10.1186/1752-1947-8-93

Cite this article as: Aguilar-Rodriguez et al.: Localized retroperitoneal Castleman's disease: a case report and review of the literature. *Journal of Medical Case Reports* 2014 **8**:93.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

